Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemiaJeongsook Yoon, Inhye E. Ahn, David Qualls et al.|Blood Advances|2025Cited by 12
Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)Austin Kim, Mark A. Murakami, Peter A. Riedell et al.|Blood|2025Cited by 4
Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)Austin I. Kim, Mark A. Murakami, Philippe Armand et al.|Blood|2024Cited by 2
Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLLJu-hee Yoon, Inhye E. Ahn, Yinglu Zhou et al.|Blood|2024Cited by 2
227 | RITUXIMAB AND EPCORITAMAB AS FIRST‐LINE THERAPY FOR PATIENTS WITH HIGH‐TUMOR BURDEN FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIALR. Merryman, Yazeed Sawalha, D. S. Wallace et al.|Hematological Oncology|2025Cited by 1